Immix Biopharma, Inc. IMMX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -74.4%+37.0pp | -54.9%+90.8pp | -182.5%-65.2pp | -162%-59.5pp | -111.4%-19.7pp | |
| Liquidity | ||||||
| Current ratio | 8.8×+7.0× | 10×+7.7× | 1.5×-1.9× | 1.2×-5.8× | 1.8×-4.0× | |
| Leverage | ||||||
| Debt-to-equity | 0×-0.1× | 0×-0.1× | 0.1×+0.1× | 0.2×+0.2× | 0.1×+0.1× | |
| Per Share | ||||||
| Book value per share | $1.52+372% | $2.85+507% | $0.26-56.6% | $0.16-81.3% | $0.32-72.9% | |
| Valuation | ||||||
| Market capitalization | $691.97M+1,008% | $275.6M+355% | $68.27M+55.7% | $62.45M+9.6% | $46.57M-35.3% | |
| Price / book | 8.2×+1.7× | 2.9×-1.6× | 8.3×+5.8× | 13.4×+11.0× | 4.9×+2.3× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Immix Biopharma, Inc.'s ratios come from?
- Every ratio is computed from Immix Biopharma, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.